Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 1039-1049

  Dorr, Robert T ^a,b   Wisner, Lee ^a   Samulitis, Betty K ^a   Landowski, Terry H ^a   Remers, William A ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b AmpliMed Corporation   (United States)

Author keywords

AMP423; Cyanoaziridine; Imexon; Preclinical; Pro oxidant

Indexed keywords

AMP 423; ANTINEOPLASTIC AGENT; IMEXON; NUCLEOPHILE; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG STRUCTURE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STRUCTURAL HOMOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HEXANONES; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; NAPHTHALENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859802410     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1784-8     Document Type: Article

References (30)

1. Iyengar BS, Dorr RT, Alberts DS, Hersh EM, Salmon SE, Remers WA (1999) Novel antitumor 2-cyanoaziridine-1-carboxamides. J Med Chem 42:510-514 (Pubitemid 29085111)
2. Salmon SE, Hersh EM (1994) Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J Natl Cancer Inst 86:228-230 (Pubitemid 24042265)
3. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE (1992) Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238-1244
4. Dorr RT, Liddil JD, Klein MK, Hersh EM (1995) Preclinical pharmacokinetics and antitumor activity of imexon. Invest New Drugs 13:113-116
5. Pourpak A, Meyers RO, Samulitis BK, Chow H-H, Kelper CY, Raymond MA, Hersh E, Dorr RT (2006) Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs 17(10):1179-1184 (Pubitemid 44673398)
6. Iyengar BS, Dorr RT, Remers WA (2004) Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem 47:218-223 (Pubitemid 38040505)
7. Dvorakova K, Payne CM, Tome M, Briehl MM, McClure T, Dorr RT (2000) Induction of oxidative stress and apoptosis in myeloma cells the aziridine-containing agent by imexon. Biochem Pharmacol 60:749-758 (Pubitemid 30621659)
8. Samulitis BK, Landowski TH, Dorr RT (2006) Correlates of imexon sensitivity in human multiple myeloma cell lines. Leuk Lymphoma 47:97-109 (Pubitemid 43101731)
9. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT (2001) Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544-3551
10. Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT (2002) Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anticancer Drugs 13:1031-1042 (Pubitemid 36020673)
11. Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S (2005) Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. Int J Gastrointest Cancer 36:15-28 (Pubitemid 41443606)
12. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow S, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr RT (2007) Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25:1779-1784 (Pubitemid 46797961)
13. Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E (2010) A phase I-II study of imexon plus dacarbazine (DTIC) in patients with unresectable metastatic melanoma. Cancer 116(15):3683-3691
14. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock A (2010) A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 29(5):634-640
15. Cohen SJ, Zalupski MM, Modiano MR, Conkling PR, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM (2010) A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol 66(2):287-294
16. Scott J, Dorr RT, Samulitis B, Landowski TH (2007) Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cells lines. Cancer Chemother Pharmacol 59:749-757 (Pubitemid 46440597)
17. Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CR, Coon A, Dorr RT (2002) Molecular and cellular characterization of imexon-resistant RPMI 8226/I myeloma cells. Mol Cancer Ther 1:185-195
18. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:5125-5130 (Pubitemid 16008277)
19. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
20. Reers M, Smith TW, Chen LB (1991) J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30(18):4480-4486
21. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, Kalyanaraman B (2003) Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med 34:1359-1368 (Pubitemid 36570409)
22. Poot M, Kavanagh TJ, Kang HC, Haugland RP, Rabinovitch PS (1991) Flow cytometric analysis of cell cycle-dependent changes in cell thiol level by combining a new laser dye with Hoechst 333421. Cytometry 12:184-187
23. Friedman DM, Boger E (1961) Colorimetric estimation of nitrogen mustards in aqueous media. Anal Chem 33:906-910
24. Christian RA, Chaffee SK, Hovick CJ, Steele WJ (1980) A stable colorimetric assay for cyclophosphamide and its alkylating metabolites based on the alkylation of 4-(4′-nitrobenzyl)-pyridine. Life Sci 27:2595-2599 (Pubitemid 11133878)
25. Bissery MC, Guenard D, Cueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845-4852
26. Samulitis BK, Landowski TH, Dorr RT (2009) Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Invest New Drugs 27:89-98
27. Tomasz M, Chowdary D, Lipman R, Shimotakahara S, Veiro D, Walker V, Verdine GL (1986) Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct. Proc Natl Acad Sci 83:6702-6706 (Pubitemid 16002302)
28. Ismail FM, Levitsky DO, Dembitsky VM (2009) Aziridine alkaloids as potential therapeutic agents. Eur J Med Chem 44:3373-3387
29. Paleo MR, Aurrecoechea N, Jung K-Y, Rapoport H (2003) Formal enantiospecific synthesis of (?)-FR900482. J Org Chem 68:130-138
30. Tomasz M, Palom Y (1997) The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 76:73-87 (Pubitemid 28078561)